ResMed CEO Michael Farrell Exercises Options, Sells 4,991 Shares

What Happened
Michael J. Farrell, ResMed’s Chairman and CEO, exercised options to acquire 4,991 shares on 2026-08-07 at an exercise price of $146.34 per share (cost ≈ $730,383) and then sold those 4,991 shares in the open market the same day at a weighted average price of $205.69 per share (proceeds ≈ $1,026,596). The filing also shows the related derivative (the option) was cancelled/converted as part of the exercise. The sale was executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-11 (filed 4 days after transaction; Form 4s are normally due within 2 business days).
• Exercise: 4,991 shares at $146.34 each → cost ≈ $730,383. (Transaction code M = option exercise.)
• Sale: 4,991 shares at weighted average $205.69 → proceeds ≈ $1,026,596. Reported sale prices ranged $202.410–$204.160 across multiple trades (footnote).
• Net difference (pre-tax): roughly $296,213 (proceeds minus exercise cost).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — sale executed under a Rule 10b5-1 plan adopted Oct 31, 2024. F2 — sale executed in multiple trades; price shown is weighted average. F3 — notes about option vesting (options vest 1/3 per year; the date listed is when options first become exercisable).

Context

• This was an exercise of stock options followed by an immediate open-market sale of the acquired shares, a common pattern used to cover exercise costs and tax obligations.
• The filing indicates the trades were made under a pre-set 10b5-1 plan, which typically means the sales were scheduled in advance and are considered routine rather than a spontaneous market-timing decision.
• As always, insider sales do not by themselves prove sentiment about the company; purchases tend to be more informative about a manager’s personal bullishness.